Nisa Investment Advisors, LLC Immuno Gen, Inc. Transaction History

Nisa Investment Advisors, LLC

$16.7 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	BUY	$12.46 - $29.95 $6,728 - $16,173	540 Added 8.4%	6,970 $206,000
Q3 2023 Nov 02, 2023	SELL	$14.09 - $19.87 $253 - $357	-18 Reduced 0.28%	6,430 $102,000
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $3,180 - $17,002	848 Added 15.14%	6,448 $121,000
Q1 2023 May 02, 2023	SELL	$3.67 - $4.92 $17,946 - $24,058	-4,890 Reduced 46.62%	5,600 $22,000
Q4 2022 Feb 02, 2023	SELL	$4.55 - $6.31 $291 - $403	-64 Reduced 0.61%	10,490 $52,000
Q3 2022 Nov 07, 2022	BUY	$4.48 - $6.47 $734 - $1,061	164 Added 1.58%	10,554 $63,000
Q2 2022 Aug 03, 2022	BUY	$3.15 - $5.76 $17,640 - $32,256	5,600 Added 116.91%	10,390 $47,000
Q1 2022 Apr 29, 2022	SELL	$4.26 - $7.48 $19,042 - $33,435	-4,470 Reduced 48.27%	4,790 $23,000
Q4 2021 Feb 03, 2022	SELL	$4.75 - $7.5 $16,482 - $26,025	-3,470 Reduced 27.26%	9,260 $52,000
Q4 2020 Jan 25, 2021	BUY	$3.7 - $7.66 $35,890 - $74,302	9,700 Added 320.13%	12,730 $82,000
Q3 2020 Oct 20, 2020	BUY	$3.45 - $4.89 $3,415 - $4,841	990 Added 48.53%	3,030 $11,000
Q2 2020 Jul 27, 2020	BUY	$3.32 - $5.34 $1,460 - $2,349	440 Added 27.5%	2,040 $9,000
Q1 2019 Apr 17, 2019	SELL	$2.41 - $5.91 $105,317 - $258,267	-43,700 Reduced 96.47%	1,600 $4,000
Q4 2018 Jan 17, 2019	BUY	$3.94 - $9.7 $175,586 - $432,280	44,565 Added 6063.27%	45,300 $217,000
Q3 2018 Oct 16, 2018	BUY	$8.6 - $11.26 $516 - $675	60 Added 8.89%	735 $7,000
Q1 2018 Apr 10, 2018	SELL	$6.7 - $12.95 $7,537 - $14,568	-1,125 Reduced 62.5%	675 $7,000
Q4 2017 Jan 12, 2018	BUY	$5.07 - $7.92 $2,332 - $3,643	460 Added 34.33%	1,800 $12,000
Q3 2017 Oct 13, 2017	BUY	$5.4 - $8.47 $7,236 - $11,349	1,340	1,340 $10,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.

Account